Back to results
US 11,654,158 B2Granted
TGFBeta signal convertor
Assignee2seventy bio, Inc.
InventorBenjamin Boyerinas
Life of this patent
Estimating the term…
Abstract
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Claims20
A lentiviral vector comprising a polynucleotide encoding a fusion polypeptide comprising:
- (a) a TGFβR2 polypeptide comprising:
- (i) an extracellular TGFβI-binding domain of TGFβR2;
- (ii) an IL-12Rβ2 transmembrane domain;
- and
- (iii) an IL-12Rβ2 intracellular signaling domain;
- (b) a viral self-cleaving 2A peptide;
- and
- (c) a TGFβR1 polypeptide comprising:
- (i) an extracellular TGFβ1-binding domain of TGFβR1;
- (ii) an IL-12Rβ1 transmembrane domain;
- and
- (iii) an IL-12Rβ1 intracellular signaling domain.
9 more elements
A lentiviral vector comprising a polynucleotide encoding a fusion polypeptide comprising:
- (a) a TGFβR2 polypeptide comprising:
- (i) an extracellular TGFβI-binding domain of TGFβR2;
- (ii) an IL-12Rβ2 transmembrane domain;
- and
- (iii) an IL-12Rβ2 intracellular signaling domain;
- (b) a viral self-cleaving 2A peptide;
- and
- (c) a TGFβR1 polypeptide comprising:
- (i) an extracellular TGFβ1-binding domain of TGFβR1;
- (ii) an IL-12Rβ1 transmembrane domain;
- and
- (iii) an IL-12Rβ1 intracellular signaling domain.
9 more elements
Dependencies are inferred from the claim text.